Scarica l'app Stockscreener
37.29
3.42%
-1.28
Dopo l'orario di chiusura:
36.86
-0.43
-1.15%
Precedente Chiudi:
$38.57
Aprire:
$38.47
Volume 24 ore:
448.49K
Relative Volume:
1.03
Capitalizzazione di mercato:
$759.05M
Reddito:
$1.77M
Utile/perdita netta:
$-123.74M
Rapporto P/E:
-4.0665
EPS:
-9.17
Flusso di cassa netto:
$-95.21M
1 W Prestazione:
-1.64%
1M Prestazione:
-57.02%
6M Prestazione:
-37.79%
1 anno Prestazione:
-32.51%
Intervallo 1D:
$36.55
$39.34
Intervallo di 1 settimana:
$34.91
$39.44
Portata 52W:
$33.01
$91.83
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Nome
Praxis Precision Medicines Inc
Settore
Industria
Telefono
617-300-8460
Indirizzo
99 HIGH STREET, 30TH FLOOR, BOSTON
Confronta PRAX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
37.29 | 759.05M | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.51 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-03 | Reiterato | H.C. Wainwright | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-08-05 | Iniziato | Oppenheimer | Outperform |
| 2024-06-24 | Iniziato | Needham | Buy |
| 2024-06-18 | Iniziato | Guggenheim | Buy |
| 2024-05-01 | Iniziato | Robert W. Baird | Outperform |
| 2023-09-19 | Iniziato | Truist | Buy |
| 2022-06-06 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2021-08-26 | Iniziato | BofA Securities | Buy |
| 2021-04-26 | Iniziato | William Blair | Outperform |
| 2020-11-11 | Iniziato | Wedbush | Outperform |
| 2020-11-10 | Iniziato | Cowen | Outperform |
| 2020-11-10 | Iniziato | Evercore ISI | Outperform |
| 2020-11-10 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Praxis Precision Medicines Inc Borsa (PRAX) Ultime notizie
HC Wainwright Has Negative Estimate for PRAX Q1 Earnings - Defense World
Praxis Precision Medicines Updates on Programs and Finances - TipRanks
New York State Common Retirement Fund Boosts Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Rhumbline Advisers Cuts Stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year Low Following Analyst Downgrade - Defense World
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Praxis Adds Six New Hires With $33.55 Stock OptionsWhat's Behind This Talent Acquisition? - StockTitan
Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences - GlobeNewswire
Praxis Precision price target lowered to $85 from $150 at Needham - Yahoo Finance
CNS Therapy Developer PRAX Lines Up Five Major Investor ConferencesWhat's Their 2025 Strategy? - StockTitan
Praxis: Still A 'Hold' Despite Interim Analysis Setback Of Ulixacaltamide (NASDAQ:PRAX) - Seeking Alpha
Praxis Precision Medicines (NASDAQ:PRAX) Given New $105.00 Price Target at HC Wainwright - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Price Target Cut to $85.00 by Analysts at Needham & Company LLC - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Given New $73.00 Price Target at Robert W. Baird - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Price Target Lowered to $85.00 at Truist Financial - Defense World
Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade) - Seeking Alpha
Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate - Benzinga India
Praxis Precision (PRAX) Stock Price Target Cut By Half - AskTraders
Praxis Precision price target lowered to $85 from $175 at Truist - TipRanks
Praxis Precision Medicines Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Praxis Precision tanks on negative ulixacaltamide news - The Pharma Letter
Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $65 From $111, Maintains Buy Rating - Marketscreener.com
Assessing Praxis Precision Medicine: Insights From 5 Financial Analysts - Benzinga
Praxis Precision Medicines: A Compelling Buy Amidst Promising Pipeline Developments - TipRanks
Praxis Precision Medicines (NASDAQ:PRAX) Shares Gap Down After Earnings Miss - Defense World
Praxis Precision Medicines (PRAX) Projected to Post Quarterly Earnings on Friday - MarketBeat
Praxis cites doubts over late-stage trial success: Wedbush downgrades (update) - MSN
Praxis Precision Medicines Provides Update on Essential3 and Corporate Update - GlobeNewswire
Praxis to advance late-stage program for lead asset despite doubts over success - MSN
Praxis stock price target cut to $61 at TD Cowen By Investing.com - Investing.com Australia
Items Tagged with 'relutrigine' - BioWorld Online
Items Tagged with 'vormatrigine' - BioWorld Online
Praxis Aims To Complete ET Trial Despite Likely Primary Endpoint Miss - Citeline News & Insights
Praxis stock price target cut to $61 at TD Cowen - Investing.com India
Wedbush Downgrades Praxis Precision Medicines to Underperform From Neutral, Cuts Price Target to $26 From $57; Shares Fall - Marketscreener.com
Market Whales and Their Recent Bets on PRAX Options - Benzinga
H.C. Wainwright sees opportunity for quick rebound from Praxis after setback - TipRanks
Truist cuts Praxis stock target to $85, maintains buy rating By Investing.com - Investing.com South Africa
Truist cuts Praxis stock target to $85, maintains buy rating - Investing.com
Praxis Precision Medicines: Navigating Challenges and Catalysts in Epilepsy Treatment - TipRanks
Buy Rating Maintained for Praxis Precision Medicines Despite Essential3 Setback, Focus on Promising Pipeline and Strong Financial Position - TipRanks
Truist Securities Adjusts Praxis Precision Medicines Price Target to $85 From $175, Maintains Buy Rating; Shares Plunge - Marketscreener.com
Recursion Pharmaceuticals, DoubleVerify Holdings, Praxis Precision Medicines - TradingView
Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Praxis Precision Medicines Says it Gets Recommendation From IDMC to Stop Study 1 of Essential3 Program - Marketscreener.com
Praxis' tremor drug trial unlikely to meet main goal -February 28, 2025 at 08:36 am EST - Marketscreener.com
Independent committee says Praxis' tremor drug trial unlikely to meet main goal -February 28, 2025 at 08:12 am EST - Marketscreener.com
Praxis Precision Medicines, Inc. SEC 10-K Report - TradingView
Praxis Suffers Clinical Trial Setback: What's Next for Their $469M Pipeline? - StockTitan
Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Down 8.5%Here's What Happened - MarketBeat
Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - MSN
Praxis Precision Medicines Inc Azioni (PRAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Praxis Precision Medicines Inc Azioni (PRAX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 14 '24 |
Sale |
80.20 |
8,239 |
660,827 |
10,301 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 14 '24 |
Option Exercise |
56.94 |
4,374 |
249,056 |
10,801 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 14 '24 |
Sale |
81.78 |
5,188 |
424,318 |
5,613 |
0.49%
1.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):